Table 1 Patient Demographics and Baseline Characteristics

From: Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial

Characteristic

N = 28

Median age, years (range)

67.5 (44,79)

Sex, n (%)

 

 Male

16 (57)

 Female

12 (43)

Race and ethnicity, n (%)

 White

16 (57)

 Asian

6 (21)

 Middle Eastern or North African

1 (4)

 Hispanic or Latino

4 (14)

 American Indian/Alaska Native

1 (4)

Baseline ECOG PS score, n (%)

 

 0

17 (61)

 1

11 (39)

Median number cycles completed (range)

5.5 (1,6)

Best response, n (%)

 

 Stable disease

19 (68)

 Partial response

7 (25)

 No imaging performed

2 (7)

  1. ECOG PS Eastern Cooperative Oncology Group Performance Status.